Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 484 participants.

Also called NCT07632898

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 484 participants (planned count) (from the registry)
Sponsor
Inhibikase Therapeutics (from the registry)
Registry
  • NCT NCT07632898
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07632898. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-23 (anticipated); primary completion 2030-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Condition
Pulmonary Arterial Hypertension (PAH)
Intervention (Drug)
IKT-001
Lead sponsor
Inhibikase Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct07632898
Content hash
e72f6e10eacc0601a89f17503c400bd08eb99b9c6eda08aacc9b482bee62f520